IceCure Medical Ltd (ICCM) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of IceCure Medical Ltd $1.93, price $1.69, upside +14.2%, quality 36 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch IceCure Medical Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range $1.59 – $348.52 · fair‑value band $1.28 – $2.41 · the $1.69 price screens below the $1.93 fair value. Dashed = 300-day average. As of Sep 27, 2026.
Follow IceCure Medical in your weekly email
Every Wednesday you see whether IceCure Medical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
IceCure Medical Ltd, a commercial-stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally.
Show more
IceCure Medical Ltd, a commercial-stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers the ProSense system, a single probe cryoablation system for the treatment of malignant breast tumors, as well as its associated disposables, including CryoProbes needles, and guiding needles/introducers; and IceSense3 system for ablation indications in urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MSense, a multi probe system for the treatment of multiple and larger tumors. The company serves hospitals, interventional radiological centers, ambulatory centers, and private clinics. IceCure Medical Ltd was incorporated in 2006 and is headquartered in Caesarea, Israel.
Stock analysis
IceCure Medical Ltd (ICCM) currently trades at $1.69, while our model-based Fair Value estimate is $1.93, implying the stock looks roughly 12.4% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.
Scenario range: $1.28 (bear) to $2.41 (bull), the price of $1.69 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
IceCure Medical Ltd reported revenue of $3.4M in FY2025 versus $4.1M in FY2021, a compound −4.9%/yr. Reported net income was −$15.1M in FY2025.
Key figures
Market cap $7.0M · P/S ratio 1.78 · EPS (TTM) $−6.56 · Return on equity −228% · Return on assets (EBIT) −82.8% · Operating margin −488% · Revenue (TTM) $3.9M · Revenue growth (YoY) +72.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 27 out of 100 (medium confidence).
What moves the price
The share trades about 94% below its 52-week high and 6% above its 52-week low.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at 14%, ICCM screens cheaper than that median.
Fair Value models
Bear $1.28Fair Value $1.93Bull $2.41
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.6/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+2.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.7%
Start year 2020 (pandemic). Over 10 years: +16.0% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.7%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−106.8% (2020) → −446.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 332 stocks
Beats the industry median on 4/6 measures
Overall it ranks above its industry peers.
Valuation
Quality Score37 · Bottom 25%
Fair Value upside+14.2% · Top 25%
Profitability
Return on assets−73.9% · Bottom 25%
Growth and dividend
Revenue growth72.8% · Top 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "IceCure Medical Ltd Fair Value". https://www.fairvalue-calculator.com/stock/ICCM
Frequently asked questions
Is IceCure Medical Ltd (ICCM) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of $1.93 versus a price of $1.69, about +14% upside (undervalued).
What is the fair value of ICCM?
Our model-based fair value for IceCure Medical Ltd is $1.93 (as of Sep 27, 2026), built from audited fundamentals. The current price: $1.69.
What is the quality score of ICCM?
IceCure Medical Ltd has a Quality Score of 36/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for IceCure Medical Ltd (ICCM)?
Our model-based price target is the fair value of $1.93 (as of Sep 27, 2026) from 1 valuation models. Cautious scenario $1.28, optimistic scenario $2.41. It is a calculation from audited fundamentals, not an analyst target.
What is the IceCure Medical Ltd stock forecast for 2026?
Our models put fair value at $1.93, about +14% upside versus a price of $1.69 (undervalued). Cautious scenario $1.28, optimistic scenario $2.41. The calculation is refreshed regularly with new filings.
What is the revenue of IceCure Medical Ltd (ICCM)?
IceCure Medical Ltd reported trailing-twelve-month revenue of about $3.9M (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of IceCure Medical Ltd (ICCM)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For IceCure Medical Ltd it is $1.93 per share (as of Sep 27, 2026), against a price of $1.69. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is IceCure Medical Ltd stock overvalued or undervalued in 2026?
As of Sep 27, 2026, ICCM trades below its calculated fair value: price $1.69, fair value $1.93, a gap of about +14% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ICCM?
No. The price is what the market pays today ($1.69); the fair value is what the company's own numbers justify ($1.93). For IceCure Medical Ltd the two are $0.2400 per share apart. That gap is exactly why we show both numbers side by side.
How much is IceCure Medical Ltd worth?
The market values IceCure Medical Ltd at about $7.0M (market capitalisation, as of Sep 27, 2026). Per share that is $1.69; our models calculate a fair value of $1.93 per share.
What do the bullish and bearish scenarios say about ICCM?
Our models span a range for IceCure Medical Ltd: cautious scenario $1.28, base $1.93, optimistic $2.41 per share (as of Sep 27, 2026, price $1.69). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of IceCure Medical Ltd (ICCM)?
Balance-sheet figures for IceCure Medical Ltd (as of Sep 27, 2026): return on equity −228.3%. They feed the Quality Score of 36/100, which measures business quality independently of the share price.
How far is ICCM from its 52-week high?
IceCure Medical Ltd trades at $1.69, about 94% below its 52-week high of $30.00 and 6% above the low of $1.59 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of $1.93 is for.
Which stocks are comparable to IceCure Medical Ltd?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is IceCure Medical Ltd stock attractive at the current price?
The data as of Sep 27, 2026: price $1.69, calculated fair value $1.93 (+14%), Quality Score 36/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ICCM calculated?
We run IceCure Medical Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $1.93, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. IceCure Medical Ltd currently trades 12 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of IceCure Medical Ltd (ICCM)?
The closing price on Oct 1, 2026 was $1.69. Our model-based fair value is $1.93, about +14% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with IceCure Medical Ltd right now?
A fairly wide model range ($1.28 to $2.41) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of IceCure Medical Ltd
How large is the market capitalisation of IceCure Medical Ltd (ICCM)?
The market capitalisation of IceCure Medical Ltd is $7.0M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of IceCure Medical Ltd (ICCM)?
The price-to-sales ratio of IceCure Medical Ltd is 1.78 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of IceCure Medical Ltd (ICCM)?
Earnings per share at IceCure Medical Ltd are $−6.56. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of IceCure Medical Ltd (ICCM)?
The return on equity (ROE) of IceCure Medical Ltd is −228% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of IceCure Medical Ltd (ICCM)?
On an EBIT basis the return on assets of IceCure Medical Ltd is −82.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of IceCure Medical Ltd (ICCM)?
The operating margin of IceCure Medical Ltd is −488% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at IceCure Medical Ltd (ICCM)?
Revenue at IceCure Medical Ltd is growing +72.8% versus a year earlier (3y avg +3.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does IceCure Medical Ltd (ICCM) generate?
The free cash flow of IceCure Medical Ltd is −$14.6M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does IceCure Medical Ltd (ICCM) hold?
IceCure Medical Ltd holds more cash than debt, $8.7M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch IceCure Medical Ltd in the live analysis
One click puts IceCure Medical Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 27, 2026